

Biological Evaluation of Products Formed from the Irradiation of Chlorpromazine with a 266 nm Laser Beam

Alexandru T^{1,2,3}, Armada A^{4,5}, Danko B^{6,7}, Hunyadi A^{6,7}, Militaru A^{1,2}, Boni M^{1,2}, Nastasa V^{1,2}, Martins A^{4,6,8,9}, Viveiros M^{3,4}, Pascu ML^{1,2,3}, Molnar J^{3,8} and Amaral L^{3,4,5,8*}

¹National Institute for Laser, Plasma and Radiation Physics, Laser Department, 077125, Magurele, Romania

²Faculty of Physics, University of Bucharest, 077125, Magurele, Romania

³COST Action BM0701 (ATENS) of the European Commission, Brussels, Belgium

⁴Group of Mycobacteria, Microbiology Unit, Institute of Hygiene and Tropical Medicine, New University of Lisbon, 1349-008 Lisbon, Portugal

⁵Centre for Malaria and Tropical Diseases (CMDT), Institute of Tropical Medicine and Hygiene, Universidade Nova de Lisboa, 1349-008 Lisbon, Portugal

⁶Institute of Pharmacognosy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary

⁷COST Action CM0804 of the European Commission, Brussels, Belgium

⁸Department of Medical Microbiology and Medical Immunology, University of Szeged, 6720 Szeged, Hungary

⁹Unit of Parasitology and Medical Microbiology, Institute of Hygiene and Tropical Medicine, New University of Lisbon, Portugal

Abstract

Varying concentrations of Chlorpromazine Hydrochloride (CPZ) were exposed to a 266 nm laser beam for varying periods of time ranging from 4 to 24 hrs and the products of irradiation were evaluated for activity against a panel of bacteria that consisted of representatives of Gram-positives and Gram-negatives that expressed different degrees of efflux pump activity, and compared to the parental unexposed compound with prolonged irradiation. Whereas the antibacterial activity of the product against *Staphylococcus aureus* and *Escherichia coli* strains was many folds greater, no activity against their efflux pumps was noted. The activity of the products of irradiation against *Salmonella enterica* serovar Enteritidis was slight. However, the products of prolonged irradiation of CPZ produced increasingly significant concentration dependent inhibition of efflux by the *Salmonella* strains.

Keywords: Laser irradiation; Photodegradation; Chlorpromazine (CPZ); *Escherichia coli*; *Salmonella enterica* serovar Enteritidis; Antimicrobial activity; Inhibition of efflux pumps.

Introduction

Exposure of compounds to a high energy laser beam for varying periods of time is known to increase their biological activity [1-3]. Exposure of Chlorpromazine Hydrochloride (CPZ) to a 266 nm laser beam has been shown to increase its activity against a reference strain of *Staphylococcus aureus* ATCC 25923 [3]. The study has been extended to include a larger range of concentrations of CPZ exposed to prolonged periods of time to a 266 nm laser beam at an average energy of 6.5 mJ. The products of irradiation were examined for altered antibacterial activity against panels of Gram-positive and Gram-negative bacteria that differed with respect to the expression of their efflux pumps as well as for activity against their efflux pumps. The results of this study support the idea that exposure of an antibacterial agent to a high energy laser beam at a wavelength that matches the maximum absorbance of the compound is a prospective way to obtain molecules with increased antibacterial activity as compared to the parental compound. With respect to activity against the efflux pumps of the studied bacteria, the products produced from the irradiation of CPZ inhibited the efflux pump of the *Salmonella* strains in a concentration dependent manner and the degree of inhibition related to the prolongation of irradiation of CPZ.

Materials

Culture media and reagents

Mueller-Hinton (MH) (Sigma, Madrid, Spain), Luria Bertani (LB) and Tryptic Soy Broth (TSB) media Oxoid (Basingstoke, Hampshire, UK) were purchased in powder form. Stock solution of Ethidium Bromide (EB) (Sigma Aldrich) at 100 mg/L prepared in distilled water. CPZ from Sigma (Madrid, Spain), higher than 98.9% pure, was dissolved in distilled water to yield a concentration of 20 mg/mL

immediately before use and protected from environmental (natural and/or artificial) light.

Bacterial strains

The panel of bacteria for evaluation of products of irradiation of CPZ consisted of Gram-positive wild-type *Staphylococcus aureus* American Type Culture Collection (ATCC) 25923 and *Staphylococcus aureus* HPV 107 (representative of the MRSA Iberian clone; it was isolated at a Portuguese hospital in 1992 and is characterized by resistance to several classes of antibiotics, particularly β -lactams, aminoglycosides, fluoroquinolones, macrolides, rifampicin and tetracycline [4,5]). The ATCC wild-type strain has an intrinsic efflux pump system and the HPV 107 strain has a plasmid containing the QacA gene which renders the bacterium multidrug resistance [6].

The Gram-negative bacteria are *Escherichia coli* K-12 AG100 (wild-type), *Escherichia coli* K-12 AG100A (efflux pump AcrAB-TolC deleted [7]), *Escherichia coli* AG100_{TET^r} (induced to high level resistance to tetracycline and over expresses its AcrAB-TolC) [7]; *Salmonella enterica* serovar Enteritidis NCTC 13349 (wild-type), *Salmonella enterica* serovar Enteritidis 104 (clinical strain), *Salmonella enterica* serovar

***Corresponding author:** Leonard Amaral, M.D., Ph.D., Centre for Tropical Diseases Malaria y Otras (CMDT), Institute of Tropical Medicine and Hygiene Universidade Nova de Lisboa, 1349-008 Lisbon, Portugal, E-mail: lamaral@ihmt.unl.pt

Received November 23, 2012; **Accepted** December 21, 2012; **Published** December 24, 2012

Citation: Alexandru T, Armada A, Danko B, Hunyadi A, Militaru A, et al. (2013) Biological Evaluation of Products Formed from the Irradiation of Chlorpromazine with a 266 nm Laser Beam. Biochem Pharmacol 2:109. doi:[10.4172/2167-0501.1000109](https://doi.org/10.4172/2167-0501.1000109)

Copyright: © 2013 Alexandru T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Enteritidis 5408 (clinical stain), *Salmonella Enteritidis* 104_{CIP} and 5408_{CIP} strains were derived from their respective parental strains by gradual exposure to ciprofloxacin which resulted in resistance to this antibiotic [8]. Whereas induced resistance of these progeny strains was due from over-expression of the *acrB* transporter of the *acrAB*-*TolC* efflux pump [8], with respect to the 104_{CIP}, resistance was in part due to the presence of a mutation in *gyrA* and two mutations in the stress gene *sox* [8].

Methods

Minimum inhibitory concentration (MIC)

MIC of the compounds were determined by the microplate broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) recommendations [9] and is defined as the lowest concentration of compound for which no visible growth is present. The MIC for each compound was determined at least three separate times.

Real-time ethidium bromide accumulation assay

The real-time activity of the compounds against efflux pumps of the panel of bacteria at concentrations at and below ½ their MIC has been described in detail [10]. This fluorometric method employs a Rotor-Gene™ 3000 Thermocycler with real time analysis software (Corbett Research, Sydney, Australia) that follows the accumulation of the universal substrate EB [9] and the data interpreted represent changes in the degree of fluorescence produced due to effects of the compounds on the activity of the efflux pump [9]. Briefly, the strains were cultured in appropriate medium until they reached an optical density at 600 nm (OD₆₀₀) of 0.6 and were then centrifuged at 13,000 rpm for 3 minutes. Pellets were resuspended in Phosphate-Buffered Saline (PBS), washed twice and resuspended in PBS containing glucose (concentration of 0.4%). The OD₆₀₀ was adjusted with PBS to 0.6, and aliquots of 45 µL were transferred to microtubes of 0.2 mL volume. 5 µL of distilled, sterile water blank control or 5 µL of the compounds dissolved in water at different concentrations was individually added to the tubes, followed by the addition of 45 µL of PBS containing a concentration of EB adjusted for different strains and by 50 µL of bacterial cells. The amount of fluorescence representing accumulated EB by the bacterium was monitored on a real-time basis and the graphs obtained reflected the degree of fluorescence generated per unit period of time.

Results

To determine efflux-modulation activity, it is necessary to use a concentration of any potential efflux pumps inhibitor that is ½ MIC or below [11], which does not affect the viability of the bacterium [12]. The MIC of the products of prolonged irradiation of CPZ against the panel of Gram-positive and Gram-negative bacteria is described by table 1; the values of the results of MIC for the irradiated compounds that present a significant antimicrobial activity against bacteria than the un-irradiated one are highlighted in this table.

- The MIC for CPZ irradiated for 4, 8, 16, and 24 hrs against the *S. aureus* ATCC 25923 and HPV 107 was 8 times lower than that of the un-irradiated CPZ control.
- The MIC for CPZ irradiated for 4, 8, 16, and 24 hrs against the wild-type *E. coli* K-12 AG100 was 8 times lower than the one obtained for the un-irradiated CPZ control.
- The MIC for the above irradiated CPZ products against *E. coli* strains K-12 AG100A, AG100_{TET} and AG100_{ATET} was as much as 16 fold lower than the one obtained with the un-irradiated CPZ control.

- For *Salmonella Enteritidis* strains, the above irradiated CPZ products produced a marginal two fold decrease (barely significant) in the MIC as compared to the un-irradiated CPZ.

These results suggest that the activity of irradiated products of CPZ is significantly greater than that produced by the un-irradiated control CPZ.

The study of accumulation of the effect of irradiated products of CPZ on the retention of EB (inhibition of efflux) was conducted at ½ their MICs and demonstrated that there is no significant activity against the efflux pumps of *S. aureus* ATCC 25923 and *S. aureus* HPV 107 and those of *E. coli* K-12 AG100, AG100A, AG100_{TET} and AG100A_{TET} (data not shown). It should be noted that concentrations of the irradiated CPZ products above the MIC did inhibit efflux (data not shown). With respect to the effect of the products of irradiation on the efflux pump of the *Salmonella* strains, as evident by the example provided by figure 1 demonstrating an inhibition of efflux of the *Salmonella* 104. As noted by figure 1, the products produced from the irradiation of CPZ inhibited the efflux pump of the *Salmonella* strains and with exception of the 24 hr irradiated product, the degree of inhibition was related to the prolongation of irradiation of CPZ. This was also true for the other strains. Not shown is the concentration dependent inhibition of efflux by the most prolonged irradiation products of CPZ. It should be noted that the effect of the products of irradiation appear to be more pronounced on the efflux pump of the 104 parental strain than that of its ciprofloxacin induced over-expressed *AcrB* transporter progeny 104_{CIP}. The reason for this is that because the latter strain has a far greater number of efflux pumps, inhibition requires higher amounts of inhibitor. Unfortunately, this basic understanding is lacking in most studies of inhibitors of efflux pumps of bacteria.

Discussion


The results obtained in this study suggest that the effect of irradiating a compound, in our case CPZ, with a 266 nm laser beam generates new species, and with exception of the *Salmonella enterica* serovar *Enteritidis* strains, the products of the irradiated CPZ demonstrated greater antimicrobial properties than the un-irradiated product against the bacteria employed in this study. Although the products of irradiation produced a barely significant reduction of the MIC of CPZ, they inhibited the efflux pump systems only of *Salmonella enterica* serovar *Enteritidis*.

Most of medicinal compounds, developed during the 20th century have their origins in phenothiazines [13]. Phenothiazines at relatively high concentrations have activity against bacteria, where they can mediate effects such as: direct inhibition of replication [14], reduced antimicrobial resistance via increased drug efflux [15], inhibition of bacterial motility [16], enhanced killing of intracellular bacteria [17], elimination of plasmids [18], and inhibition of efflux pumps of Gram-positive and Gram-negative bacteria [19].

Phenothiazines can eliminate the plasmids from bacteria (plasmid curing) due to the smaller concentration (MIC) of the agent needed to inhibit plasmid replication as opposed to those required for the inhibition of replication of the bacterium harboring the plasmid [20,21].

Phenothiazines have been shown to inhibit the NorA efflux pump of *S. aureus* [20], the Qac efflux pump of the plasmid carried by a *S. aureus* multidrug resistant strain [6] and the *AcrAB* efflux pump of *E. coli* [15].

Phenothiazines affect the activity of genes that regulate and code the *AcrAB* efflux pump of *E. coli* [7,8,15] and *Salmonella enterica*



Strains	CPZ	CPZ	CPZ	CPZ	CPZ
	unirradiated	irradiated 4 h	irradiated 8 h	irradiated 16 h	irradiated 24 h
	MIC (mg/L)	MIC (mg/L)	MIC (mg/L)	MIC (mg/L)	MIC (mg/L)
<i>Staphylococcus aureus</i> ATCC 25923	25	3.125	3.125	3.125	3.125
<i>Staphylococcus aureus</i> HPV 107	25	3.125	3.125	3.125	3.125
<i>Escherichia coli</i> K-12 AG100	25	3.125	3.125	3.125	3.125
<i>Escherichia coli</i> K-12 AG100A	25	1.56	1.56	1.56	1.56
<i>Escherichia coli</i> AG100TET8	50	3.125	3.125	3.125	3.125
<i>Escherichia coli</i> AG100ATET8	50	6.25	6.25	6.25	6.25
<i>Salmonella Enteritidis</i> NCTC 13349	50	25	25	25	25
<i>Salmonella Enteritidis</i> 104	50	25	25	25	25
<i>Salmonella Enteritidis</i> 104 _{CIP}	100	25	25	25	25
<i>Salmonella Enteritidis</i> 5408	50	25	25	25	25
<i>Salmonella Enteritidis</i> 5408 _{CIP}	50	25	25	25	25

Table 1: Minimum Inhibitory Concentrations (MIC) of the compounds for Gram-negative and Gram-positive strains.

serovar *Enteritidis* [8].

Because in our study the antimicrobial activity of the irradiated products of CPZ were many fold greater than that produced by unirradiated CPZ, and with respect to the *Salmonella* strains, had significant activity against the organism's efflux pump, it would of course be interesting to determine whether the products of irradiation also affect the genes that regulate and code for the efflux pump of *Salmonella* as previously shown for the phenothiazine thioridazine [8].

The antimicrobial activity of the irradiated products of CPZ was identical against the *S. aureus* strains ATCC 25923 and HPV 107. However, because the irradiated products at ½ their MIC have no activity against the efflux pumps of these strains, the antimicrobial activity noted must be due to some other mechanism.

Due to the composition and structure of the cell envelope, Gram-negative bacteria have much higher intrinsic levels of resistance to various antibiotics, antiseptics, dyes, and detergents than Gram-positive bacteria do [22]. *Salmonella Enteritidis* has at least nine multidrug efflux pumps [23]. One of these efflux pumps, AcrAB, is the most efficient, playing a role in both drug resistance and virulence [24]. Although for *E. coli* there are 36 drug transporters, belonging to the 4 major families of efflux transporters: MF, RND, SMR and ABC, only 21 of them can confer drug resistance either as single drug (e.g. drug-specific transporters such as TetA(B)) or as several unrelated drugs (e.g. multidrug transporters such as AcrB) [25]. For the ABC family only one ABC transporter confers drug resistance [26]. Because our study shows that the irradiated products have no activity against the efflux

pump system of *E. coli* strains whereas they inhibit the efflux pump system of the *Salmonella* strains, it may be that the active products have activity against a non-AcrAB-tolC pump of the latter organism. If this is true, then this would be the first time that a compound(s) would have this type of efflux pump-selective activity. At this time the identity of the compound(s) that produce an inhibition of efflux by *Salmonella* is not known and is the subject of our current study.

Acknowledgements

The authors from NILPRP acknowledge financing of the research by Program LAPLAS 3 PN 09 39/2009, Alexandru T and Danko B were supported by STSM grants from COST Action BM0701 and Hunyadi A from COST action CM0804. Romanian National Authority for Scientific Research, CNCS – UEFISCDI by project number PN-II-ID-PCE-2011-3-0922 and , CNDI – UEFISCDI by project number PN-II-PT-PCCA-2011-3.1-1350. The authors acknowledge grants from the European Union co-funded by the European Social Fund (TAMOP-4.2.2/B-10/1-2010-0012, and TAMOP-4.2.2A-11/1/KONV-2012-0035) A. Militaru and V. Nastasa were supported by projects POSDRU 107/1.5/S/80765 and POSDRU/88/1.5/S/56668, respectively. A. Martins and L. Amaral acknowledge the grants SFRH/BPD/81118/2011 and SFRH/BCC/51099/2010, respectively, provided by the Fundação para a Ciência e a Tecnologia, Portugal.

References

1. Hunyadi A, Danko B, Boni M, Militaru A, Alexandru T, et al. (2012) Rapid, laser-induced conversion of 20-hydroxyecdysone and its diacetone -- experimental set-up of a system for photochemical transformation of bioactive substances. Anticancer Res 32: 1291-1297.

2. Pascu ML, Nastasa V, Smarandache A, Militaru A, Martins A, et al. (2011) Direct modification of bioactive phenothiazines by exposure to laser radiation. Recent Pat Antiinfect Drug Discov 6: 147-157.

3. Pascu ML, Danko B, Martins A, Jedlinski N, Alexandru T, et al. (2013) Exposure of Chlorpromazine to 266 nm laser beam generates new species with antibacterial properties: contributions to development of new process for drug discovery. *PLoS One*, 2013 Feb 06, DOI: 10.1371/journal.pone.0055767.
4. Sanches IS, Ramirez M, Troni H, Abecassis M, Padua M, et al. (1995) Evidence for the geographic spread of a methicillin-resistant *Staphylococcus aureus* clone between Portugal and Spain. *J Clin Microbiol* 33: 1243-1246.
5. Oliveira DC, Tomasz A, de Lencastre H (2001) The evolution of pandemic clones of methicillin-resistant *Staphylococcus aureus*: identification of two ancestral genetic backgrounds and the associated mec elements. *Microb Drug Resist* 7: 349-361.
6. Costa SS, Ntokou E, Martins A, Viveiros M, Pournaras S, et al. (2010) Identification of the plasmid-encoded qacA efflux pump gene in methicillin-resistant *Staphylococcus aureus* (MRSA) strain HPV107, a representative of the MRSA Iberian clone. *Int J Antimicrob Agents* 36: 557-561.
7. Paixão L, Rodrigues L, Couto I, Martins M, Fernandes P, et al. (2009) Fluorometric determination of ethidium bromide efflux kinetics in *Escherichia coli*. *J Biol Eng* 3: 18.
8. Spengler G, Rodrigues L, Martins A, Martins M, McCusker M, et al. (2012) Genetic response of *Salmonella enterica* serotype Enteritidis to thioridazine rendering the organism resistant to the agent. *Int J Antimicrob Agents* 39: 16-21.
9. Park SH, Lim JA, Choi JS, Kim KA, Joo CK (2009) The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics. *Cornea* 28: 68-72.
10. Pagès JM, Amaral L (2009) Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. *Biochim Biophys Acta* 1794: 826-833.
11. Viveiros M, Portugal I, Bettencourt R, Victor TC, Jordaan AM, et al. (2002) Isoniazid-induced transient high-level resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 46: 2804-2810.
12. Dymek A, Armada A, Handzlik J, Viveiros M, Spengler G, et al. (2012) The activity of 16 new hydantoin compounds on the intrinsic and overexpressed efflux pump system of *Staphylococcus aureus*. *In Vivo* 26: 223-229.
13. Amaral L, Fanning S, Pagès JM (2011) Efflux pumps of gram-negative bacteria: genetic responses to stress and the modulation of their activity by pH, inhibitors, and phenothiazines. *Adv Enzymol Relat Areas Mol Biol* 77: 61-108.
14. Amaral L, Kristiansen J, Lorian V (1992) Synergic effect of chlorpromazine on the activity of some antibiotics. *J Antimicrob Chemother* 30: 556-558.
15. Viveiros M, Jesus A, Brito M, Leandro C, Martins M, et al. (2005) Inducement and reversal of tetracycline resistance in *Escherichia coli* K-12 and expression of proton gradient-dependent multidrug efflux pump genes. *Antimicrob Agents Chemother* 49: 3578-3582.
16. Molnár J, Ren J, Kristiansen JE, Nakamura MJ (1992) Effects of some tricyclic psychopharmacons and structurally related compounds on motility of *Proteus vulgaris*. *Antonie Van Leeuwenhoek* 62: 319-320.
17. Martins M, Bleiss W, Marko A, Ordway D, Viveiros M, et al. (2004) Clinical concentrations of thioridazine enhance the killing of intracellular methicillin-resistant *Staphylococcus aureus*: an in vivo, ex vivo and electron microscopy study. *In Vivo* 18: 787-794.
18. Spengler G, Miczák A, Hajdú E, Kawase M, Amaral L, et al. (2003) Enhancement of plasmid curing by 9-aminoacridine and two phenothiazines in the presence of proton pump inhibitor 1-(2-benzoxazolyl)-3,3,3-trifluoro-2-propanone. *Int J Antimicrob Agents* 22: 223-227.
19. Sabatini S, Kaatz GW, Rossolini GM, Brandini D, Fravolini A (2008) From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the *Staphylococcus aureus* NorA multidrug efflux pump. *J Med Chem* 51: 4321-4330.
20. Wainwright M, Amaral L, Kristiansen JE (2012) The evolution of antimycobacterial agents from non-antibiotics. *Open Journal of Pharmacology* 2.
21. Brown MH, Skurray RA (2001) Staphylococcal multidrug efflux protein QacA. *J Mol Microbiol Biotechnol* 3: 163-170.
22. Yu EW, Aires JR, Nikaido H (2003) AcrB multidrug efflux pump of *Escherichia coli*: composite substrate-binding cavity of exceptional flexibility generates its extremely wide substrate specificity. *J Bacteriol* 185: 5657-5664.
23. Nishino K, Latifi T, Groisman EA (2006) Virulence and drug resistance roles of multidrug efflux systems of *Salmonella enterica* serovar Typhimurium. *Mol Microbiol* 59: 126-141.
24. Nikaido E, Shirotsuka I, Yamaguchi A, Nishino K (2011) Regulation of the AcrAB multidrug efflux pump in *Salmonella enterica* serovar Typhimurium in response to indole and paraquat. *Microbiology* 157: 648-655.
25. Borges-Walmsley MI, McKeegan KS, Walmsley AR (2003) Structure and function of efflux pumps that confer resistance to drugs. *Biochem J* 376: 313-338.
26. Nishino K, Yamaguchi A (2001) Analysis of a complete library of putative drug transporter genes in *Escherichia coli*. *J Bacteriol* 183: 5803-5812.